Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFP-derived peptide adjuvant therapy after TACE for hepatocellular carcinoma
jRCTs041180155Completed
- Start
- Oct 2017
- Countries
- 1
01
Overview
Open-label, single-arm trial in hepatocellular carcinoma (HCC). Primary endpoint: Severe adverse events. Started Oct 2017; status: completed.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs041180155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180155.